Compare Agnico Eagle Mines Ltd (AEM) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agnico Eagle Mines Ltd vs Incyte Corporation — how do they compare? Agnico Eagle Mines Ltd trades at $186.05 (market cap $92.01B), while Incyte Corporation trades at $120.57 (market cap $24.54B). The key difference: Agnico Eagle Mines Ltd is far larger — about 3.7× Incyte Corporation's market cap, and Agnico Eagle Mines Ltd pays a 0.99% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| AEM | INCY | |
|---|---|---|
Market Cap | $92.01B | $24.54B |
Sector | Basic Materials | Health |
52-Week High | $252.19 | $129.93 |
52-Week Low | $130.23 | $81.61 |
Enterprise Value | $88.85B | $20.04B |
Dividend Yield | 0.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agnico Eagle Mines (AEM) trades at $180.48, up 0.93% today, with strong quarterly earnings beats and bullish analyst consensus. The stock shows robust fundamentals with a P/E of 15.56, net income margin of 40.44%, and record free cash flow of $6.82B in 2025. Recent news highlights operational strength amid gold price gains, though cost pressures are noted.
Outlook remains positive with a $219.63 price target and 67.7% buy ratings, supported by organic growth plans. Risks include rising production costs and gold price volatility. The stock offers upside potential but faces margin compression headwinds in 2026.
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agnico Eagle Mines Ltd
Agnico Eagle Mines is a gold miner operating mines in Canada, Mexico, and Finland. It also owns 50% of the Canadian Malartic mine. Agnico operated just one mine, LaRonde, as recently as 2008 before bringing its other mines on line in rapid succession in the following years. The company produced more than 1.7 million gold ounces in 2020. Agnico Eagle is focused on increasing gold production in lower-risk jurisdictions.
Read more on AEM →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
